Retinal Disorders (AMD and DME) Pulse
Retinal Disorders (AMD and DME) Pulse
$599.00
We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
Publisher: Biomedtracker
- Description
- Contents
- Samples
We performed a 5-question survey of 20 ophthalmologists who treat retinal diseases to gauge current usage and projected future usage of agents for the treatment of wet and dry age-related macular degeneration (AMD) and diabetic macular edema (DME).
Drugs and drug candidates discussed: Fovista, lampalizumab, Lucentis (ranibizumab), Eylea (aflibercept), Avastin (bevacizumab), and Ozurdex (dexamethasone-eluting implant).
Disease Group Covered: Ophthalmology
Figure: Number of patient eyes treated for WET AMD (in the last year)
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Multiple Sclerosis KOL Insight Interview 
Sign up to the